Supplemental New Drug Application For RISPERDAL(R) CONSTA(R) Submitted To The FDA For The Treatment Of Frequently Relapsing Bipolar Disorder Alkermes, Inc. (NASDAQ: ALKS) announced that its partner, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), submitted a Supplemental New Drug Application (sNDA) for RISPERDAL� CONSTA� [(risperidone) Long-Acting Injection] to the U.S. Food and Drug Administration (FDA) seeking approval for adjunctive maintenance treatment to delay the occurrence of mood episodes in patients with frequently relapsing bipolar disorder (FRBD).
Source: www.medicalnewstoday.comNursing For Women's Health Tackles Communication With Pregnant Adolescents Nurses' significant influence on pregnant adolescents and the importance of establishing effective and therapeutic communication is the focus of an article in the April/May issue of Nursing for Women's
Health, the clinical practice journal of the Association of Women's
Health, Obstetric and Neonatal Nurses (AWHONN).
Source: www.medicalnewstoday.comBioMedEcon Reports Three Times Higher Healthcare Costs Among Patients With Obsessive-Compulsive Disorder Compared To Patients With Depression BioMedEcon
Health Economics and Outcomes Research has just delivered an oral presentation summarizing the results of a pioneering study that compares
healthcare costs of patients with obsessive-compulsive disorder (OCD) to those of patients with depression. This presentation was delivered at the 31st Annual Meeting of the Society of General and Internal
Medicine (SGIM) held in Pittsburgh, Penn. This study, which was funded by Jazz Pharmaceuticals, Inc.
Source: www.medicalnewstoday.com
# posted by Network @ 9:00 PM
